BR102015024165A2 - composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso - Google Patents

composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso Download PDF

Info

Publication number
BR102015024165A2
BR102015024165A2 BR102015024165A BR102015024165A BR102015024165A2 BR 102015024165 A2 BR102015024165 A2 BR 102015024165A2 BR 102015024165 A BR102015024165 A BR 102015024165A BR 102015024165 A BR102015024165 A BR 102015024165A BR 102015024165 A2 BR102015024165 A2 BR 102015024165A2
Authority
BR
Brazil
Prior art keywords
oil
composition according
cannabinoid
combinations
acid
Prior art date
Application number
BR102015024165A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Donaduzzi Carmen
Gregory Burgos de Menezes Christian
Dário Colmenero De Oliveira Helder
Brum Junior Liberato
Donaduzzi Luiz
Moura Rosa Patricia
José Tondo Filho Volnei
Original Assignee
Prati Donaduzzi & Cia Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58288018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR102015024165(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prati Donaduzzi & Cia Ltda filed Critical Prati Donaduzzi & Cia Ltda
Priority to BR102015024165A priority Critical patent/BR102015024165A2/pt
Priority to EP16845409.8A priority patent/EP3351242A4/en
Priority to BR112018005423-2A priority patent/BR112018005423B1/pt
Priority to CN201680057462.4A priority patent/CN108366988A/zh
Priority to US15/760,918 priority patent/US20180264121A1/en
Priority to JP2018533979A priority patent/JP2018528985A/ja
Priority to PCT/BR2016/050231 priority patent/WO2017045053A1/pt
Priority to CA2998739A priority patent/CA2998739A1/en
Priority to AU2016322148A priority patent/AU2016322148A1/en
Publication of BR102015024165A2 publication Critical patent/BR102015024165A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR102015024165A 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso BR102015024165A2 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR102015024165A BR102015024165A2 (pt) 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
EP16845409.8A EP3351242A4 (en) 2015-09-18 2016-09-16 CANNABINOID-HOLDING ORAL PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION AND USE THEREOF
BR112018005423-2A BR112018005423B1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
CN201680057462.4A CN108366988A (zh) 2015-09-18 2016-09-16 包含大麻素的口服药物组合物，其制备和使用方法
US15/760,918 US20180264121A1 (en) 2015-09-18 2016-09-16 Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same
JP2018533979A JP2018528985A (ja) 2015-09-18 2016-09-16 カンナビノイドを含む経口医薬組成物、その調製及び使用のための方法
PCT/BR2016/050231 WO2017045053A1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
CA2998739A CA2998739A1 (en) 2015-09-18 2016-09-16 Oral pharmaceutical composition comprising cannabinoid, process for its preparation and use
AU2016322148A AU2016322148A1 (en) 2015-09-18 2016-09-16 Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102015024165A BR102015024165A2 (pt) 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso

Publications (1)

Publication Number Publication Date
BR102015024165A2 true BR102015024165A2 (pt) 2017-03-28

Family

ID=58288018

Family Applications (2)

Application Number Title Priority Date Filing Date
BR102015024165A BR102015024165A2 (pt) 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
BR112018005423-2A BR112018005423B1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018005423-2A BR112018005423B1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso

Country Status (8)

Country Link
US (1) US20180264121A1 (enExample)
EP (1) EP3351242A4 (enExample)
JP (1) JP2018528985A (enExample)
CN (1) CN108366988A (enExample)
AU (1) AU2016322148A1 (enExample)
BR (2) BR102015024165A2 (enExample)
CA (1) CA2998739A1 (enExample)
WO (1) WO2017045053A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019153064A1 (pt) 2018-02-09 2019-08-15 Prati, Donaduzzi & Cia Ltda Composição farmacêutica, excipiente para a composição e uso da composição

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658137A4 (en) * 2017-07-27 2020-06-03 Shaaban, Basil Adil CANNABINOID COMPOSITION WITH OPTIMIZED FATTY ACID PROFILE
US20190083622A1 (en) * 2017-10-16 2019-03-21 Joshua Raderman Cannabinoid formulations and methods including the antioxidant c60
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
EP3787614B1 (en) 2018-05-03 2024-07-31 SCF Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions and use thereof for modulating a microbiota composition of a subject
US20220304963A1 (en) * 2018-07-27 2022-09-29 Basil Shaaban Composition having an optimized fatty acid excipient profile
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
US20210186870A1 (en) * 2018-08-27 2021-06-24 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
CN108968071A (zh) * 2018-09-26 2018-12-11 江西中医药大学 代代花和火麻仁组合物在制备改善记忆力减退或治疗抑郁症药物或保健功能饮料中的应用
WO2020123809A1 (en) 2018-12-14 2020-06-18 Natural Extraction Systems, LLC Compositions and methods related to anionic cannabinoid molecules
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
CA3040547C (en) * 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
DK3826630T3 (da) * 2019-07-21 2022-09-26 Scf Pharma Inc Sammensætninger af cannabinoider med polyumættede fedtsyremonoglycerider og anvendelser heraf
EP4010024A4 (en) * 2019-08-08 2023-05-03 Neptune Wellness Solutions Inc. ORAL FORMULATIONS OF CANNABIS EXTRACTS AND THEIR PRODUCTION PROCESSES
US12419855B2 (en) 2019-08-28 2025-09-23 Natural Extraction Systems, LLC Compositions comprising cannabinoid ions that are dissolved in glycerol
MX2022002548A (es) * 2019-09-09 2022-03-22 Cardiol Therapeutics Inc Composiciones medicinales estables de cannabidiol.
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
CN111603443B (zh) * 2020-06-12 2022-06-28 苏州旺山旺水生物医药有限公司 一种稳定的cbd组合物及其应用
WO2022026960A1 (en) 2020-07-31 2022-02-03 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
JP2023039414A (ja) * 2021-09-08 2023-03-20 株式会社東洋新薬 経口組成物
EP4601629A1 (en) * 2022-10-12 2025-08-20 Leiutis Pharmaceuticals LLP Novel liquid oral formulations of cannabidiol
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof
CA3236758A1 (en) * 2023-07-24 2025-06-17 Poviva Corp Compositions and methods for treating epilepsy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501003A (ja) * 1990-09-13 1994-01-27 スミスクライン・ビーチャム・コーポレイション 非水性液状経口懸濁液
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20070129340A1 (en) * 2004-02-06 2007-06-07 Chugai Seiyaku Kabushiki Kaisha Ed-71 preparation
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
EP2642982A2 (en) * 2010-11-22 2013-10-02 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
CA2872689C (en) * 2012-05-07 2021-03-30 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
CA2928834A1 (en) * 2013-06-13 2014-12-18 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
AU2015266897B2 (en) * 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
GB2542155B (en) * 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019153064A1 (pt) 2018-02-09 2019-08-15 Prati, Donaduzzi & Cia Ltda Composição farmacêutica, excipiente para a composição e uso da composição

Also Published As

Publication number Publication date
EP3351242A1 (en) 2018-07-25
US20180264121A1 (en) 2018-09-20
CN108366988A (zh) 2018-08-03
EP3351242A4 (en) 2019-05-15
WO2017045053A1 (pt) 2017-03-23
BR112018005423B1 (pt) 2020-06-23
JP2018528985A (ja) 2018-10-04
AU2016322148A1 (en) 2018-04-12
CA2998739A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
BR102015024165A2 (pt) composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
Stella et al. Cannabinoid formulations and delivery systems: Current and future options to treat pain
CN111787910B (zh) 包含大麻素和泊洛沙姆的口服药物制剂
AU2022201441B2 (en) Stable cannabinoid formulations
ES3021218T3 (en) Dilutable formulations of cannabinoids and processes for their preparation
US10617733B2 (en) Orally consumable cannabinoid composition including lecithin
JP2023507472A (ja) カンナビノイド経口製剤
AU2015266897B2 (en) Stable cannabinoid formulations
US20210186870A1 (en) Improved cannabinoid bioavailability
BRPI0910094B1 (pt) Composição de goma de mascar, e, blíster
BR112019026877A2 (pt) composições para distúrbios do sono e tratamentos do mesmo
BR112020027070A2 (pt) Composição e método para poupar opióides
JP2022543703A (ja) Ｃｂｄ製剤およびその使用
WO2020146478A1 (en) Cannabinoid formulations for treating alcohol hangover
WO2022245900A2 (en) Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof
US20230058895A1 (en) Physiologically acceptable eutectic mixtures of cannabidiol
RU2795027C2 (ru) Фармацевтический препарат
DE29707005U1 (de) Stabilisiertes Arzneimittel enthaltend Cysteinylderivate
BR102017020661B1 (pt) Forma farmacêutica em suspensão compreendendo aripiprazol, composição farmacêutica em suspensão compreendendo aripiprazol e seu uso
BR102017020661A2 (pt) Forma farmacêutica, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]